5[3]Gillissen A,Nowak D.Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy[J].Respir Med,1998,92(4):609-623.
6[4]Teramolo S,Suzuki M,Ohga E,el al.Effects of ambroxol on spontaneous or stimulated generation of reactive oxygen species by bronchoalveolar lavage cells harvested from patients with or without chronic obstructive pulmonary diseases[J1.Pharmacology.1999,59(3):135-141.
7[6]Kido H,Okmnura Y,Yamada H,et al.Secretory leukoprotease inhibitor and pulmonary surfactant serve as principal defenses against influenza A virus infection in the airway and chemical agents up-regulating their levels may have therapeutic potential[J].Biol Chem,2004,385(11):1029-1034.
8Lusuardi M,Cape 1 li A,Carli S,etal.Role of surfactant in chronic obst ructive pulmonary disease:therapeuticimplications.Respiration,1992,59(Suppl 1): 28-32.
9Gillissen A,Nowak D.Characterization of N-acetylcysteine and ambroxol inanti-oxedant therapy.Respir Med,1998,92(4):609-623.
10Houtmeyers E.Effects of drugs on mucus clearance.Eur Respir J,1999,1 4(2):452-467.
